Prognostic and clinicopathological significance of long noncoding RNA H19 overexpression in human solid tumors: evidence from a meta-analysis

Abstract

BackgroundMany studies have reported that the expression level of lncRNA H19 was increased in various tumors. LncRNA H19 may play a significant role in cancer occurrence and development. An increased level of H19 was also associated with poor clinical outcomes of cancer patients.Results12 eligible studies were screened, with a total of 1437 cancer patients. From the results of meta-analysis, as for prognosis, the patients with high expression of lncRNA H19 were shorter in OS (HR=1.08, 95% CI: 1.05-1.12). Statistical significance was also showed in subgroup meta-analysis stratified by the cancer type, analysis type and sample size. In addition, the patients detected with high H19 expression may be poorer in DFS (HR=1.27; 95% CI = 0.97-1.56). As for clinicopathology, it showed that increased H19 was related to poor histological grades (OR=2.31, 95% CI: 1.12-4.75), positive lymph node metastasis (OR=2.29, 95 % CI: 1.21-4.34) and advanced clinical stage (OR=4.83, 95% CI: 3.16-7.39).Materials and MethodsEligible studies were collected by retrieving keywords in PubMed, Web of Science, Embase, CNKI and Wanfang database, from 1966 to April 23, 2016. This quantitative meta-analysis was performed with Stata SE12.0 and RevMan5.3 software. It aimed to explore the association between H19 expression level and prognosis and clinicopathology.ConclusionsLncRNA-H19 may be a novel molecular marker for predicting solid tumors. It can also be a predictive factor of clinicopathological features in various cancers. Further studies are needed to verify the clinical utility of H19 in human cancers.

Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients

“…Aberrant expression of lncRNAs exerts impacts on the tumor biological processes and often correlated with aggressive progression and prognosis. Consequently, lncRNAs, as promising biomarkers for tumor prognosis and monitoring, have attracted great attentions [ 29 – 31 ].…”

The LncRNA H19/miR‐193a‐3p axis modifies the radio‐resistance and chemotherapeutic tolerance of hepatocellular carcinoma cells by targeting PSEN1

“…It was also demonstrated that lncRNAs counted much in modifying the chemo‐sensitivity, for instance, up‐regulated lncRNA lncARSR was observed to promote doxorubicin resistance in HCC via modulating PTEN‐PI3K/Akt pathway . Of note, lncRNA H19, a paternally imprinted gene located in 11p15.5, was increasingly found to be over‐expressed within various cancers, including HCC, glioblastoma, gallbladder cancer, gastric cancer, and so on . To be specific, inhibition of lncRNA H19 and miR‐675 expression may promote migration and invasion of HCC cells though AKT/GSK‐3β/Cdc25A signaling pathways .…”

“…10 Of note, lncRNA H19, a paternally imprinted gene located in 11p15.5, was increasingly found to be over-expressed within various cancers, including HCC, glioblastoma, gallbladder cancer, gastric cancer, and so on. [11][12][13][14] To be specific, inhibition of lncRNA H19 and miR-675 expression may promote migration and invasion of HCC cells though AKT/GSK-3β/Cdc25A signaling pathways. 15 Hence, it was hypothesized that lncRNA H19 might play an oncogenic role in HCC, and also it might affect the chemo-and radio-tolerance of HCC.…”

The clinicopathological characteristic associations of long non-coding RNA gene H19 polymorphisms with uterine cervical cancer

“…MiR-675, which is known as one of the most important transcripts in the H19 locus, is located at exon 1 and implicated in the carcinogenesis and tumor invasiveness [11]. LncRNA H19 has been reported to be predictive of clinicopathological characteristics and H19 expression was associated with histological grades, clinical stages and lymph node metastasis status using a meta-analysis [12,13].…”